Чланци са овлашћеним јавним приступом - Stewart WolmarkСазнајте више
Није доступно нигде: 17
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised …
S Loibl, J O'Shaughnessy, M Untch, WM Sikov, HS Rugo, MD McKee, ...
The lancet oncology 19 (4), 497-509, 2018
Овлашћења: US National Institutes of Health
Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project …
EP Mamounas, JH Jeong, DL Wickerham, RE Smith, PA Ganz, SR Land, ...
Journal of Clinical Oncology 26 (12), 1965-1971, 2008
Овлашћења: US National Institutes of Health
The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04.
MS Roh, GA Yothers, MJ O'connell, RW Beart, HC Pitot, AF Shields, ...
Journal of Clinical Oncology 29 (15_suppl), 3503-3503, 2011
Овлашћења: US National Institutes of Health
Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial
EP Mamounas, H Bandos, BC Lembersky, JH Jeong, CE Geyer, ...
The Lancet Oncology 20 (1), 88-99, 2019
Овлашћења: US National Institutes of Health, Health Research Board, Ireland
Symptom measurement in the Breast Cancer Prevention Trial (BCPT)(P-1): psychometric properties of a new measure of symptoms for midlife women
D Cella, SR Land, CH Chang, R Day, JP Costantino, N Wolmark, ...
Breast cancer research and treatment 109, 515-526, 2008
Овлашћења: US National Institutes of Health
Primary outcome results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically …
DN Krag, SJ Anderson, TB Julian, A Brown, SP Harlow, JP Costantino, ...
Journal of clinical oncology 28 (18_suppl), LBA505-LBA505, 2010
Овлашћења: US National Institutes of Health
The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40.
HD Bear, G Tang, P Rastogi, CE Geyer, A Robidoux, JN Atkins, L Baez, ...
Journal of Clinical Oncology 29 (18_suppl), LBA1005-LBA1005, 2011
Овлашћења: US National Institutes of Health
A randomized clinical trial of adjuvant chemotherapy for radically resected locoregional relapse of breast cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37
IL Wapnir, S Aebi, CE Geyer, D Zahrieh, RD Gelber, SJ Anderson, ...
Clinical breast cancer 8 (3), 287-292, 2008
Овлашћења: US National Institutes of Health
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer
B Fisher, J Bryant, N Wolmark, E Mamounas, A Brown, ER Fisher, ...
Journal of Clinical Oncology 41 (10), 1795-1808, 2023
Овлашћења: US National Institutes of Health
Impact of BMI in patients with early hormone receptor–positive breast cancer receiving endocrine therapy with or without palbociclib in the PALLAS trial
G Pfeiler, D Hlauschek, EL Mayer, C Deutschmann, S Kacerovsky-Strobl, ...
Journal of Clinical Oncology 41 (33), 5118-5130, 2023
Овлашћења: Cancer Research UK
Benefit of oxaliplatin in stage III colon cancer according to IDEA risk groups: findings from the ACCENT database of 4934 patients
O Margalit, B Boursi, M Rakez, A Thierry, G Yothers, N Wolmark, ...
Clinical colorectal cancer 20 (2), 130-136, 2021
Овлашћења: US National Institutes of Health
Patient-reported outcomes (PROs) comparison of 5-FU and capecitabine (cape) with concurrent radiotherapy (RT) for neoadjuvant treatment of rectal cancer: Results of NSABP R-04.
G Yothers, PA Ganz, SH Lopa, CY Ko, DL Wickerham, N Wolmark
Journal of Clinical Oncology 30 (4_suppl), 391-391, 2012
Овлашћења: US National Institutes of Health
Multigene predictors developed on breast cancer cell lines to predict patient chemotherapy response: A validation study on the NSABP B-27 trial.
K Shen, G Tang, JP Costantino, SJ Anderson, C Kim, KL Pogue-Geile, ...
Journal of Clinical Oncology 29 (15_suppl), 1029-1029, 2011
Овлашћења: US National Institutes of Health
Effect of serial sectioning and immunohistochemistry (IHC) on sentinel lymph nodes (SLNs) on the false-negative rate (FNR) of SLN biopsy (SLNB): Results from NSABP B-32.
EP Mamounas, SJ Anderson, TB Julian, DN Krag, D Weaver, T Ashikaga, ...
Journal of Clinical Oncology 29 (27_suppl), 86-86, 2011
Овлашћења: US National Institutes of Health
Effect of axillary dissection for occult detected sentinel nodes metastases on survival: NSABP B-32.
TB Julian, SJ Anderson, EP Mamounas, DN Krag, D Weaver, T Ashikaga, ...
Journal of Clinical Oncology 29 (27_suppl), 80-80, 2011
Овлашћења: US National Institutes of Health
Preliminary results of centralized HER2 testing in DCIS of the breast: NSABP B-43.
KP Siziopikou, MA Cobleigh, SJ Anderson, TB Julian, DW Arthur, P Zheng, ...
Journal of Clinical Oncology 29 (15_suppl), 588-588, 2011
Овлашћења: US National Institutes of Health
Reply to R. Glynne-Jones et al
MS Roh, LH Colangelo, MJ O'Connell, M Deutsch, N Wolmark
Journal of Clinical Oncology 28 (18), e307-e307, 2010
Овлашћења: US National Institutes of Health
Доступно негде: 137
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
P Cortazar, L Zhang, M Untch, K Mehta, JP Costantino, N Wolmark, ...
The Lancet 384 (9938), 164-172, 2014
Овлашћења: US National Institutes of Health
Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from …
DN Krag, SJ Anderson, TB Julian, AM Brown, SP Harlow, JP Costantino, ...
The lancet oncology 11 (10), 927-933, 2010
Овлашћења: US National Institutes of Health
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
ANJ Tutt, JE Garber, B Kaufman, G Viale, D Fumagalli, P Rastogi, ...
New England Journal of Medicine 384 (25), 2394-2405, 2021
Овлашћења: US National Institutes of Health, Cancer Research UK, National Institute for …
Публикације и информације о финансирању аутоматски одређује рачунарски програм